Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
复制标题
DOI：
10.1038/s41408-021-00546-9
复制
发表时间：
2021-09-14
影响因子：
12.8
通讯作者：
Notarangelo LD
中科院分区：
文献类型：
--
作者：
Cattaneo C;Cancelli V;Imberti L;Dobbs K;Sottini A;Pagani C;Belotti A;Re A;Anastasia A;Quaresima V;Tucci A;Chiorini JA;Su HC;Cohen JI;Burbelo PD;Rossi G;Notarangelo LD
血液恶性肿瘤（HM）患者在COVID-19后产生有效体液免疫应答的能力尚不清楚。进行了一项前瞻性研究，以监测滤泡性淋巴瘤（FL）、弥漫性大B细胞淋巴瘤（DLBCL）、慢性淋巴组织增生性疾病（CLD）、多发性骨髓瘤（MM）或骨髓增生异常/骨髓增生综合征（MDS/MPN）患者对SARS-CoV-2的免疫应答。在鼻拭子变为PCR阴性后+1、+3、+6个月测量SARS-CoV-2核衣壳（N）和刺突（S）蛋白的抗体（Ab）水平。研究了45例患者（9例FL，8例DLBCL，8例CLD，10例MM，10例MDS/MPS）和18例对照。HM患者和对照组之间的平均抗N和抗S-Ab水平相似，并且具有相同的行为，抗N Ab水平在+6个月时下降，抗S-Ab保持稳定。HM患者的血清转化率低于对照组。在淋巴瘤患者中，平均抗体水平和血清转换率低于其他HM患者，主要是因为所有9名在COVID-19前6个月内接受利妥昔单抗治疗的患者均未能产生抗N和抗S-Ab。只有1名在COVID-19后需要血液学治疗的患者在6个月后血清阳性消失。未观察到再感染。这些结果可以为HM患者的疫苗接种政策和临床管理提供信息。
The ability of patients with hematologic malignancies (HM) to develop an effective humoral immune response after COVID-19 is unknown. A prospective study was performed to monitor the immune response to SARS-CoV-2 of patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), chronic lymphoproliferative disorders (CLD), multiple myeloma (MM), or myelodysplastic/myeloproliferative syndromes (MDS/MPN). Antibody (Ab) levels to the SARS-CoV-2 nucleocapsid (N) and spike (S) protein were measured at +1, +3, +6 months after nasal swabs became PCR-negative. Forty-five patients (9 FL, 8 DLBCL, 8 CLD, 10 MM, 10 MDS/MPS) and 18 controls were studied. Mean anti-N and anti-S-Ab levels were similar between HM patients and controls, and shared the same behavior, with anti-N Ab levels declining at +6 months and anti-S-Ab remaining stable. Seroconversion rates were lower in HM patients than in controls. In lymphoma patients mean Ab levels and seroconversion rates were lower than in other HM patients, primarily because all nine patients who had received rituximab within 6 months before COVID-19 failed to produce anti-N and anti-S-Ab. Only one patient requiring hematological treatment after COVID-19 lost seropositivity after 6 months. No reinfections were observed. These results may inform vaccination policies and clinical management of HM patients.
登录
查看更多内容
影响因子：
13.6
作者：
Peluso MJ;Takahashi S;Hakim J;Kelly JD;Torres L;Iyer NS;Turcios K;Janson O;Munter SE;Thanh C;Donatelli J;Nixon CC;Hoh R;Tai V;Fehrman EA;Hernandez Y;Spinelli MA;Gandhi M;Palafox MA;Vallari A;Rodgers MA;Prostko J;Hackett J Jr;Trinh L;Wrin T;Petropoulos CJ;Chiu CY;Norris PJ;DiGermanio C;Stone M;Busch MP;Elledge SK;Zhou XX;Wells JA;Shu A;Kurtz TW;Pak JE;Wu W;Burbelo PD;Cohen JI;Rutishauser RL;Martin JN;Deeks SG;Henrich TJ;Rodriguez-Barraquer I;Greenhouse B
通讯作者：
Greenhouse B
DOI：
10.1016/s2352-3026(21)00110-1
发表时间：
2021-06
期刊：
The Lancet. Haematology
影响因子：
--
作者：
Bird S;Panopoulou A;Shea RL;Tsui M;Saso R;Sud A;West S;Smith K;Barwood J;Kaczmarek E;Panlaqui C;Kaiser M;Stern S;Pawlyn C;Boyd K
通讯作者：
Boyd K
影响因子：
82.9
作者：
Long, Quan-Xin;Liu, Bai-Zhong;Huang, Ai-Long
通讯作者：
Huang, Ai-Long
影响因子：
6.5
作者：
Fox, Thomas A.;Troy-Barnes, Ethan;Ardeshna, Kirit M.
通讯作者：
Ardeshna, Kirit M.
影响因子：
20.3
作者：
Herishanu Y;Avivi I;Aharon A;Shefer G;Levi S;Bronstein Y;Morales M;Ziv T;Shorer Arbel Y;Scarfò L;Joffe E;Perry C;Ghia P
通讯作者：
Ghia P